000296171 001__ 296171
000296171 005__ 20250124091442.0
000296171 0247_ $$2pmid$$apmid:39783714
000296171 0247_ $$2ISSN$$a1552-5260
000296171 0247_ $$2ISSN$$a1552-5279
000296171 0247_ $$2doi$$aDOI:10.1002/alz.095214
000296171 037__ $$aDKFZ-2025-00098
000296171 041__ $$aEnglish
000296171 082__ $$a610
000296171 1001_ $$aLohner, Valerie$$b0
000296171 245__ $$aAssociations of biomarkers of neurodegenerative diseases with mild neurocognitive disorder in a cohort of patients with stable coronary heart disease
000296171 260__ $$aHoboken, NJ$$bWiley$$c2024
000296171 3367_ $$2DRIVER$$aarticle
000296171 3367_ $$2DataCite$$aOutput Types/Journal article
000296171 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1737706420_24793$$xOther
000296171 3367_ $$2BibTeX$$aARTICLE
000296171 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000296171 3367_ $$00$$2EndNote$$aJournal Article
000296171 500__ $$aDeveloping Topics: Poster presentation
000296171 520__ $$aCoronary heart disease (CHD) is a well-known risk factor for cognitive impairment and dementia, and blood biomarkers of neurodegenerative diseases may be utilised to identify people at higher risk of cognitive decline. Here, we aimed to investigate prospective associations between these biomarkers and mild neurocognitive disorder (MiND) after a follow-up of ten years in patients with stable CHD, and potential effect modification by hypercholesterolemia and ApoE genotype.Biomarkers of neurodegenerative diseases (glial fibrillary acidic protein (GFAP), neurofilament light chain (NfL), and phosphorylated tau181 (p-tau181)) were measured in baseline blood serum samples using the Single-Molecule Array (Simoa) Technology (Quanterix, USA) in a subset (n = 363) of a cohort of patients with stable CHD. MiND was defined as scores ≤ 21.8 on the Cognitive Telephone Screening Instrument (COGTEL). Hypercholesterolemia was categorised into none (normal total cholesterol (TC) levels without statin use), normal TC levels with statin use, or increased TC levels independent of statin use. We evaluated prospective associations of biomarkers of neurodegenerative disease with MiND using multivariable logistic regression models, adjusted for age, sex, study centre, hearing impairment, and comorbidities. We additionally checked for biomarker×ApoE genotype and biomarker×hypercholesterolemia interactions.At follow-up, 55 (15.2%) patients had developed MiND. Higher levels of NfL were associated with increased risks of developing MiND (OR (95%-CI) per SD increase: 1.44 (1.01-2.04)). Associations of p-tau181 with MiND were depending on hypercholesterolemia, but not on ApoE genotype. Higher levels of p-tau181 were associated with lower odds of developing MiND in patients without hypercholesterolemia (OR (95%-CI) per SD increase: 0.09 (0.01-0.39)) and higher odds of developing MiND in patients with increased TC levels (OR (95%-CI) per SD increase: 7.83 (1.72-103.20)), but not in patients with normal TC levels using statins. Levels of GFAP were not associated with MiND.Preliminary analyses suggest that NfL and p-tau181 predict MiND after ten years in patients with stable CHD, and that the association of p-tau181 with MiND was modified by hypercholesterolemia. This might imply that a deterioration in cognitive performance in this population might be halted through early management of hypercholesterolemia, however, more research is warranted.
000296171 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000296171 588__ $$aDataset connected to DataCite, PubMed, , Journals: inrepo02.dkfz.de
000296171 650_7 $$2NLM Chemicals$$aBiomarkers
000296171 650_7 $$2NLM Chemicals$$atau Proteins
000296171 650_7 $$2NLM Chemicals$$aGlial Fibrillary Acidic Protein
000296171 650_7 $$2NLM Chemicals$$aNeurofilament Proteins
000296171 650_7 $$2NLM Chemicals$$aneurofilament protein L
000296171 650_7 $$2NLM Chemicals$$aApolipoproteins E
000296171 650_2 $$2MeSH$$aHumans
000296171 650_2 $$2MeSH$$aMale
000296171 650_2 $$2MeSH$$aFemale
000296171 650_2 $$2MeSH$$aAged
000296171 650_2 $$2MeSH$$aBiomarkers: blood
000296171 650_2 $$2MeSH$$atau Proteins: blood
000296171 650_2 $$2MeSH$$aCognitive Dysfunction: blood
000296171 650_2 $$2MeSH$$aCoronary Disease: blood
000296171 650_2 $$2MeSH$$aHypercholesterolemia: blood
000296171 650_2 $$2MeSH$$aGlial Fibrillary Acidic Protein: blood
000296171 650_2 $$2MeSH$$aProspective Studies
000296171 650_2 $$2MeSH$$aMiddle Aged
000296171 650_2 $$2MeSH$$aNeurofilament Proteins: blood
000296171 650_2 $$2MeSH$$aApolipoproteins E: genetics
000296171 650_2 $$2MeSH$$aRisk Factors
000296171 650_2 $$2MeSH$$aGenotype
000296171 7001_ $$aPerna, Laura$$b1
000296171 7001_ $$0P:(DE-He78)c67a12496b8aac150c0eef888d808d46$$aSchöttker, Ben$$b2$$udkfz
000296171 7001_ $$aPerneczky, Robert$$b3
000296171 7001_ $$aKliegel, Matthias$$b4
000296171 7001_ $$0P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aBrenner, Hermann$$b5$$udkfz
000296171 7001_ $$aMons, Ute$$b6
000296171 773__ $$0PERI:(DE-600)2201940-6$$aDOI:10.1002/alz.095214$$gVol. 20 Suppl 8$$pe095214$$tAlzheimer's and dementia$$v20 Suppl 8$$x1552-5260$$y2024
000296171 909CO $$ooai:inrepo02.dkfz.de:296171$$pVDB
000296171 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)c67a12496b8aac150c0eef888d808d46$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000296171 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000296171 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000296171 9141_ $$y2024
000296171 915__ $$0StatID:(DE-HGF)3001$$2StatID$$aDEAL Wiley$$d2023-10-25$$wger
000296171 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bALZHEIMERS DEMENT : 2022$$d2023-10-25
000296171 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-25
000296171 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-25
000296171 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-25
000296171 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-10-25
000296171 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-25
000296171 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-10-25
000296171 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-10-25
000296171 915__ $$0StatID:(DE-HGF)9910$$2StatID$$aIF >= 10$$bALZHEIMERS DEMENT : 2022$$d2023-10-25
000296171 9201_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x0
000296171 980__ $$ajournal
000296171 980__ $$aVDB
000296171 980__ $$aI:(DE-He78)C070-20160331
000296171 980__ $$aUNRESTRICTED